These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 36404729)

  • 21. Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?
    Lai E; Astara G; Ziranu P; Pretta A; Migliari M; Dubois M; Donisi C; Mariani S; Liscia N; Impera V; Persano M; Tolu S; Balconi F; Pinna G; Spanu D; Pireddu A; Saba G; Camera S; Musio F; Puzzoni M; Pusceddu V; Madeddu C; Casadei Gardini A; Scartozzi M
    Crit Rev Oncol Hematol; 2021 Jan; 157():103167. PubMed ID: 33271389
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapeutic approaches in Hepatocellular carcinoma: Building blocks of hope in near future.
    Minaei N; Ramezankhani R; Tamimi A; Piryaei A; Zarrabi A; Aref AR; Mostafavi E; Vosough M
    Eur J Cell Biol; 2023 Mar; 102(1):151284. PubMed ID: 36584598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
    Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
    Front Immunol; 2020; 11():1037. PubMed ID: 32547550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma.
    Zhu Y; Qin LX
    Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):420-429. PubMed ID: 35977874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics and future treatment strategies.
    Liu X; Lu Y; Qin S
    Future Oncol; 2021 Jun; 17(17):2243-2256. PubMed ID: 33663220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging drugs for the treatment of hepatocellular carcinoma.
    Ayoub WS; Jones PD; Yang JD; Martin P
    Expert Opin Emerg Drugs; 2022 Jun; 27(2):141-149. PubMed ID: 35642526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in systemic therapy for the first-line treatment of unresectable HCC.
    Vogel A; Bathon M; Saborowski A
    Expert Rev Anticancer Ther; 2021 Jun; 21(6):621-628. PubMed ID: 33499684
    [No Abstract]   [Full Text] [Related]  

  • 28. Immunotherapy Updates in Advanced Hepatocellular Carcinoma.
    Singh A; Beechinor RJ; Huynh JC; Li D; Dayyani F; Valerin JB; Hendifar A; Gong J; Cho M
    Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33946408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapies for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Current and developing strategies.
    Argemi J; Ponz-Sarvise M; Sangro B
    Adv Cancer Res; 2022; 156():367-413. PubMed ID: 35961706
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets.
    Luo XY; Wu KM; He XX
    J Exp Clin Cancer Res; 2021 May; 40(1):172. PubMed ID: 34006331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects.
    Liu Z; Liu X; Liang J; Liu Y; Hou X; Zhang M; Li Y; Jiang X
    Front Immunol; 2021; 12():765101. PubMed ID: 34675942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy for hepatocellular carcinoma.
    Childs A; Aidoo-Micah G; Maini MK; Meyer T
    JHEP Rep; 2024 Oct; 6(10):101130. PubMed ID: 39308986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy for advanced hepatocellular carcinoma, where are we?
    Zhang L; Ding J; Li HY; Wang ZH; Wu J
    Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188441. PubMed ID: 33007432
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma.
    Catalano M; Casadei-Gardini A; Vannini G; Campani C; Marra F; Mini E; Roviello G
    Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1353-1365. PubMed ID: 34289756
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rapidly Evolving Landscape and Future Horizons in Hepatocellular Carcinoma in the Era of Immuno-Oncology.
    Kang SM; Khalil L; El-Rayes BF; Akce M
    Front Oncol; 2022; 12():821903. PubMed ID: 35433430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials.
    Ozer M; George A; Goksu SY; George TJ; Sahin I
    Front Oncol; 2021; 11():801379. PubMed ID: 34956912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent developments with immunotherapy for hepatocellular carcinoma.
    Waidmann O
    Expert Opin Biol Ther; 2018 Aug; 18(8):905-910. PubMed ID: 29995439
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New Therapeutics for HCC: Does Tumor Immune Microenvironment Matter?
    Khanam A; Kottilil S
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613878
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapy of Hepatocellular Carcinoma.
    Heinrich B; Czauderna C; Marquardt JU
    Oncol Res Treat; 2018; 41(5):292-297. PubMed ID: 29705790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evolving therapeutic strategies for advanced hepatocellular carcinoma.
    Qureshi A; Michel M; Lerner J; Dasanu CA
    Expert Opin Pharmacother; 2021 Dec; 22(18):2495-2506. PubMed ID: 34252328
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.